• About
  • Licensing
  • Podcasting
  • Contact

AudioMedica.com

  • Public Health
  • Oncology
  • Cardiovascular
  • General Medicine

Tagged: ecco

  • Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer
    • in Oncology
    • — 15 Feb, 2008

    Oral Capecitabine: As Good As Fluorouracil Second Line for Metastatic Colorectal Cancer

    David Cunningham
    David Cunningham
    REFERENCE: Abstract 3012, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    DAVID CUNNINGHAM, Royal Marsden Hospital, London
    The oral agent capeticabine is just as effective as fluorouracil for treating patients whose metastatic colorectal cancer
    …
    Read more
    Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone
    • in Oncology
    • — 1 Feb, 2008

    Hormone Refractory Prostate Cancer: Increased Progression-Free Survival With Satraplatin and Prednisone

    Cora Sternberg
    Cora Sternberg
    REFERENCE: Abstract 4010, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    CORA STERNBERG, San Camillo and Forlanini Hospital, Rome
    Satraplatin could provide a new option for patients with hormone refractory prostate cancer, by giving
    …
    Read more
  • Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
    • in Oncology
    • — 16 Nov, 2007

    Two New Second-Line Options For Patients With Advanced or Metastatic Non-Small Cell Lung Cancer

    Jean-Yves Douillard
    Jean-Yves Douillard
    Gordon McVie
    Gordon McVie

    REFERENCE: Abstracts: 6507 & 2LB, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    JEAN-YVES DOUILLARD, Centre René Gauducheau, Nante
    COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

    The vinca alkaloid vinflunine and
    …
    Read more
    Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer
    • in Oncology
    • — 2 Nov, 2007

    Endothelin Antagonist Keeps Patients with Hormone Refractory Prostate Cancer Alive Longer

    Nicholas James
    Nicholas James
    Gordon McVie
    Gordon McVie

    REFERENCE: Abstract: 3LB (Presidential Session), ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    NICHOLAS JAMES, Birmingham University
    COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

    A new drug has improved overall survival
    …
    Read more
  • Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer
    • in Oncology
    • — 16 Oct, 2007

    Neoadjuvant Trastuzumab: Marked Benefit in HER2-Positive Inflammatory Breast Cancer

    Jose Baselga
    Jose Baselga
    Gordon McVie
    Gordon McVie

    REFERENCE: ABSTRACT 2030, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    JOSE BASELGA, Vall d’Hebron University Hospital, Barcelona
    COMMENT: GORDON MCVIE, European Institute of Oncology, Milan

    Neoadjuvant trastuzumab for patients with HER2-positive
    …
    Read more
    Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer
    • in Oncology
    • — 1 Oct, 2007

    Intraperitoneal Catumaxomab Prolongs Survival in Patients With Malignant Ascites from Ovarian Cancer

    Markus Heiss
    Markus Heiss

    REFERENCE: ABSTRACT 5001, ECCO 14, The European Cancer Conference, Barcelona, 23 – 27 September 2007
    MARKUS HEISS, Klinikum Cologne, Merheim
    For patients with malignant ascites as a result of ovarian cancer, a novel intraperitoneal therapy adding the trifunctional
    …
    Read more
  • Breast Cancer: Further Support for Trastuzumab from Combined Analysis
    • in ECCO 2005 · Oncology
    • — 30 Oct, 2005

    Breast Cancer: Further Support for Trastuzumab from Combined Analysis

    Edward Romond
    Edward Romond

    Edward Romond, University of Kentucky, Lexington
    More data for trastuzumab comes from a combined analysis of two large, parallel trials: NSABP B-31 and NCCTG N9831. Both looked at adding trastuzumab to doxorubicin and cyclophosphamide followed by paclitaxel.
    [audio:https://www.audiomedica.com/podcasting/ajo_13.8/02.edward_romond.mp3] …

    Read more
  • Sign up for AudioMedica.com news

    * = required field
    Speciality




  • Home
  • Tagged: ecco

© Copyright 2022 AudioMedica.com. Typegrid Theme by WPBandit.